Table 3.
Group A | Group B | Group C | p-valuea | ||
---|---|---|---|---|---|
n (%) | 13 (35.1) | 9 (24.3) | 15 (40.6) | ||
Sex (%) | Female | 8 (61.5) | 6 (66.7) | 5 (33.3) | 0.239 |
Male | 5 (38.5) | 3 (33.3) | 10 (66.7) | ||
Anomalies (%) | No | 12 (92.3) | 7 (77.8) | 10 (66.7) | 0.307 |
Yes | 1 (7.7) | 2 (22.2) | 5 (33.3) | ||
Age at HPE in days [median (IQR)] | 82.00 (64.00–86.00) | 76.00 (39.00–106.00) | 70.00 (54.00–84.50) | 0.810 | |
BA type (%) | Fetal | 2 (15.4) | 4 (44.4) | 4 (26.7) | 0.333 |
Perinatal | 11 (84.6) | 5 (55.6) | 11 (73.3) | ||
Ishak index [mode (range)] | 4 (1–6) | 5 (1–6) | 6 (1–6) | 0.754 | |
Ishak index | 1–4 | 7 (58.3) | 4 (44.4) | 7 (46.7) | 0.835 |
5–6b | 5 (41.7) | 5 (55.6) | 8 (53.3) | ||
Age at liver cirrhosis in months [median (IQR)] | 24.00 (12.25–41.75) | 7.00 (7.00–15.50) | 8.00 (6.75–9.00) | 0.042 | |
Number of cholangitis attacks (%) | No attacks | 12 (92.3) | 5 (55.6) | 10 (66.7) | 0.304 |
1 attack | 1 (7.7) | 2 (22.2) | 3 (20.0) | ||
>1 attack | 0 (0.0) | 2 (22.2) | 2 (13.3) | ||
Outcome at 3 months after HPE (%) | TB <30 µmol/L and colored stools | 9 (69.2) | 1 (11.1) | 5 (33.3) | 0.007 |
TB 30–90 µmol/L and colored stools | 3 (23.1) | 3 (33.3) | 1 (6.7) | ||
TB >90 µmol/L and/or acholic stools | 1 (7.7) | 5 (55.6) | 9 (60.0) | ||
Outcome 2 years after HPE (SNL, death or Tx) (%) | SNL | 12 (92.3) | 3 (33.3) | 7 (46.7) | 0.007 |
Other (death or Tx) | 1 (7.7) | 6 (66.7) | 8 (53.3) |
n, number; HPE, hepatoportoenterostomy; IQR, interquartile range; BA, biliary atresia; TB, total bilirubin; SNL, survival with native liver; Tx, transplantation.
Values are numbers for nominal variables and median (range) for continuous variables. The characteristics were compared across groups using ANOVA and the Kruskal–Wallis test for continuous variables and Fisher's exact test for categorical variables.
The p-values in parentheses correspond to comparison between group A, group B, and group C.
Ishak fibrotic stages 5 and 6 represent incomplete and complete cirrhosis.